Assessment of the Antibacterial Efficacy of Halicin against Pathogenic Bacteria

Artificial intelligence (AI) is a new technology that has been employed to screen and discover new drugs. Using AI, an anti-diabetic treatment (Halicin) was nominated and proven to have a unique antibacterial activity against several harmful bacterial strains, including multidrug-resistant bacteria. This study aims to explore the antibacterial effect of halicin and microbial susceptibility using the zone of inhibition and the minimum inhibition concentration (MIC) values while assessing the stability of stored halicin over a period of time with cost-effective and straightforward methods. Linear regression graphs were constructed, and the correlation coefficient was calculated. The new antibacterial agent was able to inhibit all tested gram-positive and gram-negative bacterial strains, but in different concentrations-including the A. baumannii multidrug-resistant (MDR) isolate. The MIC of halicin was found to be 16 mu g/mL for S. aureus (ATCC BAA-977), 32 mu g/mL for E. coli (ATCC 25922), 128 mu g/mL for A. baumannii (ATCC BAA-747), and 256 mu g/mL for MDR A. baumannii. Upon storage, the MICs were increased, suggesting instability of the drug after approximately a week of storage at 4 degrees C. MICs and zones of inhibition were found to be high (R = 0.90 to 0.98), suggesting that halicin has a promising antimicrobial activity and may be used as a wide-spectrum antibacterial drug. However, the drug's pharmacokinetics have not been investigated, and further elucidation is needed.

Automated summary

The study demonstrates that Halicin is a novel antibacterial agent with broad-spectrum activity, inhibiting various harmful bacteria including multidrug-resistant strains. However, the stability of the drug may be compromised after storage, necessitating further investigation.